myStoria secures $1.6 million in seed funding, with Graphite Ventures leading the investment.

      The Ontario startup integrates AI with trained human experts to assist patients in managing PCOS, endometriosis, fertility, and perimenopause, which are conditions known for their lengthy diagnostic delays and disjointed care. The funding round was led by Graphite Ventures.

      When a patient gets referred to a specialist, receives an unclear test result, or discovers a diagnosis in their portal before speaking with their doctor, the healthcare system inadvertently assigns them a second job. They must take on the roles of project manager, medical historian, insurance coordinator, and advocate, without any training, tools, or support. myStoria aims to create the necessary infrastructure for these individuals.

      The startup has successfully raised $1.625 million in a seed funding round led by Graphite Ventures, with additional contributions from Conexus Venture Capital, Adrenaline Fund, Phoenix Fire Fund, and various strategic angel investors.

      The company initially focused on reproductive health, particularly fertility and IVF, which are areas characterized by high rates of dismissal, prolonged diagnostic intervals, and fragmented care pathways. Founder and CEO Jessica Chalk drew from her own six-year experience with infertility, during which she underwent multiple treatments costing over $100,000, leading her to develop the platform she desperately needed but couldn't find.

      This seed funding allows myStoria to widen its reach across the entire reproductive health spectrum, addressing PCOS, endometriosis, perimenopause, and hormonal health with condition-specific pathways. The platform utilizes a human-in-the-loop model that merges AI with trained professionals. At its core is a “Context Engine,” a unique layer that organizes a user’s complete health information—such as documents, audio, photos, symptoms, and appointment history—into a structured format that is optimally understood by AI.

      Each interaction builds on the previously retained history. Trained professionals review the AI-generated suggestions and provide clinical context, aiming for responses that are personalized, accurate, and informed by the comprehensive health picture instead of generic information.

      The platform will be available on iOS and Android, adopting a freemium model. Aaron Bast, GP at Graphite Ventures, characterized the investment as infrastructure-oriented, stating that myStoria is “not just another consumer app,” but a “defensible infrastructure play” that secures the patient’s longitudinal health data. Graphite typically invests in seed-stage B2B and digital health firms in Canada, writing checks in the range of $500K to $1.5M.

      The myStoria funding round reaches the upper limit of this range, incorporating a larger syndicate. Alex Shimla, Principal at Conexus Venture Capital, noted that the company is “creating the patient-owned infrastructure the system has lacked.” The long-term vision is not confined to specific conditions; reproductive health serves as an entry point to a model that could ultimately assist patients dealing with cancer, heart disease, autoimmune conditions, or any complex care scenario where the patient assumes the role of their own care coordinator.